Annexon Inc

ANNXNASDAQ · USD
3.47USD0.00 (-2.81%)
139

Annexon Inc (ANNX) Covered Calls

Annexon Inc trades in the Biotechnology industry with an IV Rank of 96.43%, high versus the past year. ANNX's highest covered call setup is the $10.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 180.11% out of the money with 32 days to expiration, a 185.71% return until expiration, and a 2,118.30% theoretical annualized return. Across the setups shown, annualized returns run from 431.12% to 2,118.30% at strikes between $5.00 and $11.00, with 32 to 60 days to expiration, as of Nov 16, 2026.

Read more

Running ANNX covered calls helps you generate income from Annexon Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ANNX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ANNX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANNX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ANNX covered call is worth writing.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis.

2026-12-183210.00180.110.200.40663.00185.712118.30-5.60+0.248,2990.20
2026-12-18328.00124.090.102.95453.00126.891447.35-2.80+0.64222.85
2027-01-156011.00208.120.150.95758.00212.321291.64-4.20+0.3411,0040.80
2026-12-18327.0096.080.253.20368.00103.081175.77-7.00+0.698,8732.95
2027-01-156010.00180.110.200.75663.00185.711129.76-5.60+0.327,4420.55
2026-12-18326.0068.070.351.00278.0077.87888.22-9.80+0.446850.65
2027-01-15608.00124.090.650.90508.00142.30865.64-18.21+0.446,1310.25
2027-01-15607.0096.080.801.35423.00118.49720.80-22.41+0.541,7200.55
2026-12-18325.0040.060.801.05223.0062.46712.49-22.41+0.559,2440.25
2027-01-15606.0068.070.103.80253.0070.87431.12-2.80+0.742723.70

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank96.43% High
  • Market cap (M$)662
  • 52 weeks high-51.67%
  • 52 weeks low16.05%
  • Analyst recommendationStrong Buy
    1.36
  • Target price$17.00
    389.91% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.03
  • EPS growth next 5 years52.84%

As of Nov 17, 2026